CombinatoRx, Incorporated and Charley’s Fund/Nash Avery Foundation Collaborate to Develop Novel Agents for Duchenne Muscular Dystrophy

CAMBRIDGE, Mass. & SOUTH EGREMONT, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced a research collaboration with Charley’s Fund and the Nash Avery Foundation, both nonprofit organizations founded to support Duchenne muscular dystrophy (DMD) research. The collaboration will seek to identify novel disease-modifying multi-targeted treatments for DMD, the most common form of muscular dystrophy.
MORE ON THIS TOPIC